Urigen Pharmaceuticals Completes $2.1 Million Financing
06 August 2007 - 2:33PM
Business Wire
Urigen Pharmaceuticals, Inc. (URGP.OB), a specialty pharmaceutical
company focused on the development of treatments for urological
disorders, has secured financing totaling 2.1 million dollars led
by Platinum � Montaur Life Sciences, LLC. WBB Securities, LLC acted
as the finder for the transaction. The proceeds from the financing
will be used to advance Urigen�s URG101 program for Painful Bladder
Syndrome and URG301 program for Overactive Bladder. �Securing this
financing provides the resources we need to move forward with our
clinical trials and execute on our business plan,� said Bill
Garner, Chief Executive Officer of Urigen Pharmaceuticals. �We have
a strong, experienced management team behind Urigen Pharmaceuticals
that is committed to commercializing drugs for the treatment of
urological disorders.� About Urigen Pharmaceuticals, Inc. Urigen
Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to the development and commercialization of therapeutic
products for urological disorders. Urigen's two lead programs
target significant unmet medical needs and major market
opportunities in urology. Urigen's URG101, a proprietary
combination of approved drugs that is instilled into the bladder,
targets painful bladder syndrome, which affects approximately 10.5
million men and women in North America. Urigen's URG301, a
proprietary dosage form of an approved drug that is locally
delivered to control urinary urgency, targets acute urgency in
females diagnosed with an overactive bladder, another major unmet
need that is insufficiently managed by presently available
overactive bladder drugs. For further information, please visit
Urigen's website at http://www.urigen.com. Forward-Looking
Statement This press release may contain forward-looking
statements. These statements may be identified by the use of
forward-looking terminology such as "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "should," or "will," or
the negative thereof or other variations thereon or comparable
terminology. Urigen has based these forward-looking statements on
current expectations, assumptions, estimates and projections. While
Urigen believes that these expectations, assumptions, estimates and
projections are reasonable, such forward-looking statements are
only predictions and involve known and unknown risks and
uncertainties, many of which are beyond its control. Given these
risks and uncertainties, investors and security holders are
cautioned not to place undue reliance on such forward-looking
statements. Urigen does not undertake any obligation to update any
such statements or to publicly announce the results of any
revisions to any such statements to reflect future events or
developments.